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The Universal Definition of Myocardial Infarction (UDMI)1 classifies myocardial infarction 
(MI) into 5 subtypes, of which type 1 and type 2 MI are the most common and relevant to 
practicing clinicians.  Type 1 MI is defined as MI caused by acute atherothrombotic mechanisms, 
with type 2 MI defined as MI resulting from myocardial oxygen supply/demand mismatch 
without acute atherothrombosis.  The UDMI recognizes multiple potential causes of type 2 MI, 
including “demand side” abnormalities such as tachyarrhythmia or severe hypertension, and 
“supply side” issues such as severe anemia, hypoxemia or hypotension. Type 2 MI may occur 
with or without obstructive coronary disease, with the threshold for type 2 MI lower in patients 
with fixed obstructive CAD.  
Type 2 MI is common and is associated with substantial risk for cardiac (and noncardiac) 
death and major adverse cardiac events.2 Research to date has been limited largely to 
observational studies that have used varying definitions and adjudication criteria for type 2 MI, 
focusing on prevalence, risk factors, and prognosis, with almost no data on treatment.2  Recently, 
an ICD-10 code was introduced for type 2 MI, and it is hoped that this will facilitate research 
using administrative data.3 However, we believe that the current definition for type 2 MI is too 
phenotypically heterogeneous to permit adequate study or reliable coding by hospital 
administrators.  
Importantly, the UDMI includes under the umbrella of type 2 MI several acute coronary 
processes that obstruct blood flow, including spontaneous coronary artery dissection (SCAD), 
coronary embolism and coronary vasospasm. We believe that these specific diagnoses are a poor 
fit in the category of type 2 MI: from both a pathophysiological and clinical perspective, they are 
more closely aligned with type 1 MI.  SCAD, coronary embolism, and vasospasm are acute 
“supply side” obstructive processes that have clinical presentations and initial diagnostic and 
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management approaches that are similar to type 1 MI. They are usually spontaneous 
presentations, without an obvious precipitating event. These conditions typically are initially 
triaged as suspected acute coronary syndromes (ACS), treated with guideline-recommended 
therapies for ACS, and evaluated with early coronary imaging. The diagnosis is usually made in 
the cardiac catheterization laboratory, with subsequent treatment determined by findings from 
coronary imaging. In contrast, most other etiologies causing type 2 MI, including severe 
tachycardia and hypertension, anemia, and hypoxemia, are apparent at the time of clinical 
presentation, and diagnosed based on clinical criteria, with coronary angiography delayed or 
deferred.   
Applying the same diagnosis of type 2 MI to such phenotypically distinct patients has 
clear disadvantages for clinical management, and negatively impacts the quality of research into 
type 2 MI.  Reporting the epidemiology, outcomes and treatment responses of type 2 MI, as 
currently defined, is of little value other than making sure that these diagnoses do not “muddy” 
the interpretation of type 1 MI.   On the other hand, including patients without acute 
atherothrombosis in the type 1 MI category also creates problems.  Clinical trials and guideline 
recommendations for management of ACS are only applicable to type 1 MI. For example, 
applying therapies tested in atherothrombosis, such as parenteral anticoagulation and 
intracoronary stenting, to patients with SCAD, may be harmful.4  Evidenced-based therapies 
exist for coronary vasospasm and are emerging for SCAD, with coronary embolism typically 
managed empirically based on the source of embolism. However, such therapies are clearly 
distinct from those used to treat acute atherothrombosis. 
We propose consideration of a modest redefinition of type 1 and type 2 MI (figure), with 
type 1 MI defined by acute coronary obstruction or reduction in coronary blood flow rather than 
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by atherothrombosis.  This would move SCAD, coronary embolism and coronary vasomotor 
abnormalities (including epicardial vasospasm and microvascular dysfunction) into the type 1 MI 
category.  We further propose subclassifying type 1 MI based on the underlying 
pathophysiology, with type 1A MI being the typical atherothrombosis category and the other 
etiologies having separate subclassifications (figure).  Type 2 MI would be defined as MI due to 
acute supply/demand mismatch without acute coronary obstruction. We propose further 
subclassifying type 2 MI into those with or without obstructive CAD (figure), as the subsequent 
management approaches differ substantially based on the presence of severe CAD. As an 
important corollary, modification of ICD codes to improve specificity would be an important 
step forward for research and quality improvement in patients with MI caused by factors other 
than atherothrombosis.   
We believe that this redefinition would better align with modern approaches to diagnosis 
and management of the spectrum of patients with MI.  It would facilitate research into specific 
diagnostic subcategories and identification of optimal treatment approaches.  This designation 
would also eliminate the need for a separate classification scheme for myocardial infarction with 
no obstructive coronary disease (MINOCA).5  Each of the categories of MINOCA would fit 
within the new MI definition construct.  Also, the creation of subcategories (Type 1A, 1B, etc) 
would allow room for additional MI phenotypes, as new information on pathophysiology 
becomes available, without altering the fundamental structure of the classification.   
Although some may view differences between the UDMI and our proposed revision as 
little more than administrative detail, we would argue that alignment of diagnosis with clinical 
presentation, pathophysiology, and diagnostic approach is an essential step to address current 
knowledge gaps.  Moreover, accurate diagnosis has direct implications for quality reporting, as 
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evidence based standards exist only for MI due to atherothrombosis. Clinicians should be held 
accountable only for adhering to process and performance measures for those patients in whom 
the measures apply.  Finally, and arguably most importantly, as we enter the precision medicine 
era, it is imperative that our diagnoses be as precise as possible.  
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Figure Legend 
 
Figure. Proposed revision to Universal Definition of Myocardial Infarction (UDMI).   The 
proposal redefines type 1 and type 2 MI based on the presence or absence of acute coronary 
obstruction, with subclassifications based on underlying pathophysiology.  This differs from the 
current UDMI by categorizing spontaneous coronary dissection, coronary embolism and 
vasospasm as type 1 MI, and subclassifying type 2 MI based on the presence or absence of fixed 
obstructive coronary disease.   
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